Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART

English version České info

In order to design strategies for eradication of HIV-1 from infected individuals, detailed insight into the HIV-1 reservoirs that persist in patients on suppressive antiretroviral therapy (ART) is required. In this regard, most studies have focused on integrated (proviral) HIV-1 DNA forms in cells circulating in blood. However, the majority of proviral DNA is replication-defective and archival, and as such, has limited ability to reveal the dynamics of the viral population that persists in patients on suppressive ART. In contrast, extrachromosomal (episomal) viral DNA is labile and as a consequence is a better surrogate for recent infection events and is able to inform on the extent to which residual replication contributes to viral reservoir maintenance. To gain insight into the diversity and compartmentalization of HIV-1 under suppressive ART, we extensively analyzed longitudinal peripheral blood mononuclear cells (PBMC) samples by deep sequencing of episomal and integrated HIV-1 DNA from patients undergoing raltegravir intensification. Reverse-transcriptase genes selectively amplified from episomal and proviral HIV-1 DNA were analyzed by deep sequencing 0, 2, 4, 12, 24 and 48 weeks after raltegravir intensification. We used maximum likelihood phylogenies and statistical tests (AMOVA and Slatkin-Maddison (SM)) in order to determine molecular compartmentalization. We observed low molecular variance (mean variability ≤0.042). Although phylogenies showed that both DNA forms were intermingled within the phylogenetic tree, we found a statistically significant compartmentalization between episomal and proviral DNA samples (P<10⁻⁶ AMOVA test; P = 0.001 SM test), suggesting that they belong to different viral populations. In addition, longitudinal analysis of episomal and proviral DNA by phylogeny and AMOVA showed signs of non-chronological temporal compartmentalization (all comparisons P<10⁻⁶) suggesting that episomal and proviral DNA forms originated from different anatomical compartments. Collectively, this suggests the presence of a chronic viral reservoir in which there is stochastic release of infectious virus and in which there are limited rounds of de novo infection. This could be explained by the existence of different reservoirs with unique pharmacological accessibility properties, which will require strategies that improve drug penetration/retention within these reservoirs in order to minimise maintenance of the viral reservoir by de novo infection.

Vyšlo v časopise: Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART. PLoS Pathog 7(10): e32767. doi:10.1371/journal.ppat.1002314
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002314

Souhrn

Zdroje

1. PalmerSWiegandAPMaldarelliFBazmiHMicanJM 2003 New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41 4531 4536

2. PalmerSMaldarelliFWiegandABernsteinBHannaGJ 2008 Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105 3879 3884

3. BaileyJRSedaghatARKiefferTBrennanTLeePK 2006 Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80 6441 6457

4. JoosBFischerMKusterHPillaiSKWongJK 2008 HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 105 16725 16730

5. KiefferTLFinucaneMMNettlesREQuinnTCBromanKW 2004 Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 189 1452 1465

6. ChunTWJustementJSMoirSHallahanCWMaenzaJ 2007 Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 195 1762 1764

7. ChunTWNickleDCJustementJSLargeDSemerjianA 2005 HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115 3250 3255

8. GunthardHFFrostSDLeigh-BrownAJIgnacioCCKeeK 1999 Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 73 9404 9412

9. Martinez-PicadoJFrostSDIzquierdoNMorales-LopetegiKMarfilS 2002 Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. J Virol 76 12344 12348

10. SharkeyMTriquesKKuritzkesDRStevensonM 2005 In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 79 5203 5210

11. SharkeyMETeoIGreenoughTSharovaNLuzuriagaK 2000 Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 6 76 81

12. BrennanTPWoodsJOSedaghatARSilicianoJDSilicianoRF 2009 Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 83 8470 8481

13. SahuGKSarriaJCCloydMW 2010 Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy. J Virol 84 8348 8352

14. MiddletonTLimHBMontgomeryDRockwayTTangH 2004 Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles. Antiviral Res 64 35 45

15. SvarovskaiaESBarrRZhangXPaisGCMarchandC 2004 Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J Virol 78 3210 3222

16. BuzonMJMassanellaMLlibreJMEsteveADahlV 2010 HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16 460 465

17. LlibreJBuzónMMassanellaMEsteveADahlV 2011 Treatment intensification with raltegravir in subjects with sustained HIV-1 viremia suppression: a randomized 48 weeks study. Antivir Ther In press

18. TamuraKDudleyJNeiMKumarS 2007 MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24 1596 1599

19. BorderiaAVCodonerFMSanjuanR 2007 Selection promotes organ compartmentalization in HIV-1: evidence from gag and pol genes. Evolution 61 272 279

20. SanjuanRCodonerFMMoyaAElenaSF 2004 Natural selection and the organ-specific differentiation of HIV-1 V3 hypervariable region. Evolution 58 1185 1194

21. ExcoffierLSmousePEQuattroJM 1992 Analysis of molecular variance inferred from metric distances among DNA haplotypes: application to human mitochondrial DNA restriction data. Genetics 131 479 491

22. ZarateSPondSLShapshakPFrostSD 2007 Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol 81 6643 6651

23. SlatkinMMaddisonWP 1989 A cladistic measure of gene flow inferred from the phylogenies of alleles. Genetics 123 603 613

24. YuklSAShergillAKMcQuaidKGianellaSLampirisH 2010 Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. Aids 24 2451 2460

25. BullMELearnGHMcElhoneSHittiJLockhartD 2009 Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol 83 6020 6028

26. ChunTWCarruthLFinziDShenXDiGiuseppeJA 1997 Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387 183 188

27. ChunTWFinziDMargolickJChadwickKSchwartzD 1995 In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1 1284 1290

28. ChunTWStuyverLMizellSBEhlerLAMicanJA 1997 Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94 13193 13197

29. FinziDBlanksonJSilicianoJDMargolickJBChadwickK 1999 Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5 512 517

30. FinziDHermankovaMPiersonTCarruthLMBuckC 1997 Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 1295 1300

31. WongJKHezarehMGunthardHFHavlirDVIgnacioCC 1997 Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278 1291 1295

32. ZhuWJiaoYLeiRHuaWWangR 2011 Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly Active Antiretroviral Therapy. PLoS One 6 e21081

33. TokoyodaKZehentmeierSHegazyANAlbrechtIGrunJR 2009 Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 30 721 730

34. ChomontNEl-FarMAncutaPTrautmannLProcopioFA 2009 HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15 893 900

35. ChunTWDaveyRTJrOstrowskiMShawn JustementJEngelD 2000 Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 6 757 761

36. NoeAPlumJVerhofstedeC 2005 The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother 55 410 412

37. VerhofstedeCNoeADemecheleerEDe CabooterNVan WanzeeleF 2004 Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr 35 473 483

38. GrossmanZPolisMFeinbergMBLeviIJankelevichS 1999 Ongoing HIV dissemination during HAART. Nat Med 5 1099 1104

39. LiuSLRodrigoAGShankarappaRLearnGHHsuL 1996 HIV quasispecies and resampling. Science 273 415 416

40. VargheseVShahriarRRheeSYLiuTSimenBB 2009 Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 52 309 315

41. EdgarRC 2004 MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32 1792 1797

42. PosadaD 2008 jModelTest: phylogenetic model averaging. Mol Biol Evol 25 1253 1256

43. Kosakovsky PondSLFrostSD 2005 Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol 22 1208 1222

44. ExcoffierLLavalGSchneiderS 2005 Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 1 47 50

45. TamuraKNeiM 1993 Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 10 512 526